Aileron Therapeutics, Inc. (NASDAQ:ALRN) Short Interest Down 8.7% in October

Aileron Therapeutics, Inc. (NASDAQ:ALRN - Get Free Report) was the recipient of a large decline in short interest during the month of October. As of October 31st, there was short interest totalling 233,300 shares, a decline of 8.7% from the October 15th total of 255,600 shares. Currently, 1.2% of the company's shares are sold short. Based on an average daily volume of 74,800 shares, the days-to-cover ratio is presently 3.1 days.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the business. KG&L Capital Management LLC bought a new stake in shares of Aileron Therapeutics during the 3rd quarter worth approximately $46,000. Texas Capital Bank Wealth Management Services Inc grew its holdings in shares of Aileron Therapeutics by 65.9% in the first quarter. Texas Capital Bank Wealth Management Services Inc now owns 26,171 shares of the company's stock worth $174,000 after purchasing an additional 10,398 shares during the last quarter. Warberg Asset Management LLC purchased a new position in Aileron Therapeutics in the 2nd quarter worth about $86,000. Sigma Planning Corp increased its stake in Aileron Therapeutics by 68.3% in the 3rd quarter. Sigma Planning Corp now owns 212,410 shares of the company's stock worth $752,000 after buying an additional 86,185 shares during the period. Finally, Geode Capital Management LLC lifted its holdings in Aileron Therapeutics by 34.8% during the 3rd quarter. Geode Capital Management LLC now owns 229,817 shares of the company's stock valued at $814,000 after buying an additional 59,370 shares in the last quarter. Institutional investors own 90.89% of the company's stock.

Aileron Therapeutics Trading Down 13.3 %

NASDAQ:ALRN traded down $0.44 during midday trading on Friday, hitting $2.87. 125,411 shares of the company traded hands, compared to its average volume of 94,756. The firm's fifty day moving average is $3.48 and its 200-day moving average is $3.13. The firm has a market capitalization of $62.19 million, a P/E ratio of -0.92 and a beta of 2.35. Aileron Therapeutics has a 12-month low of $1.57 and a 12-month high of $7.42.

Aileron Therapeutics (NASDAQ:ALRN - Get Free Report) last released its quarterly earnings results on Wednesday, August 14th. The company reported ($0.45) EPS for the quarter, missing analysts' consensus estimates of ($0.25) by ($0.20). On average, research analysts expect that Aileron Therapeutics will post -1.41 EPS for the current fiscal year.

Aileron Therapeutics Company Profile

Aileron Therapeutics, Inc, a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 1b clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF).